Folic acid nudges blood sugar down, but too little to matter

Interest keeps growing in whether everyday dietary supplements can meaningfully improve blood sugar control, both for preventing type 2 diabetes and for managing it. Folic acid, a cheap and widely taken B vitamin, has been proposed as one such candidate, with individual trials pointing in different directions. Scattered small trials cannot settle a question like this on their own, which is exactly what pooling is for. This review set out to combine every randomised trial of folic acid supplementation and its effect on the standard markers of glycaemic control in adults.

The authors searched Scopus, PubMed, Embase and ISI Web of Science for randomised controlled trials published up to March 2021, using combinations of related keywords. From 1814 detected studies, twenty-four trials reported at least one relevant outcome: fasting blood glucose, fasting insulin, HbA1c or the HOMA-IR insulin resistance score. Mean changes between intervention and control groups were pooled, and the team also ran dose-response and meta-regression analyses to test whether the dose of folic acid or the duration of supplementation changed the size of the effect.

Folic acid supplementation produced significant but small reductions: fasting blood glucose fell by 2.17 mg/dL, fasting insulin by 1.63 pmol/L, and HOMA-IR by 0.40. HbA1c, the marker that captures average blood sugar over months, showed no significant change at 0.27%. The dose-response analysis found a non-linear relationship for HOMA-IR, but the meta-regression found no linear link between dose, duration and the changes in fasting glucose, insulin or HOMA-IR. In other words, taking more folic acid or taking it for longer did not straightforwardly produce bigger effects.

This pooling confirms that folic acid has a genuine effect on fasting glucose and insulin, but it also sizes that effect honestly, and the size is the story: the authors state plainly that the reductions were small and may limit clinical applications for adults with type 2 diabetes. The failure of HbA1c to move is particularly telling, since it is the marker clinicians rely on to judge blood sugar control over time. The review leaves open whether particular groups respond better and calls for further research to confirm the findings.

Folic acid has legitimate uses, and nothing here argues against taking it for those reasons. What this review deflates is the idea of folic acid as a blood sugar supplement: the measurable effects exist but are small enough that the reviewers doubt their clinical relevance, and the long-term marker did not change at all. For anyone focused on their metabolic health, this is a reason to keep expectations with the things that move these numbers substantially rather than with a B vitamin. A real effect and a useful effect are not the same thing.